Tonix Pharmaceuticals logo — company profile

Tonix Pharmaceuticals

Founded 2007 United States United States 169 employees Post Ipo Equity Biopharma, Biotechnology +1

General Information

Company Name Tonix Pharmaceuticals
Founded Year 2007
Location United States United States +1
Employees 169
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Tonix Pharmaceuticals moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a biopharmaceutical company, publicly traded on NASDAQ (ticker: TNXP). The Company is focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease. Tonix markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are each indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS development portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. The Company’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, which also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases. Tonix Pharmaceuticals was founded in 2007 and operates within the industries of Biopharma, Biotechnology, and Pharmaceutical. The last investment in the company was a Post-IPO Equity investment on 12 June 2024.

Funding Rounds & Investors (15)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 12 Jun 2024
Post-IPO Equity •••••• - 28 Mar 2024
Post-IPO Equity •••••• - 20 Dec 2023
Post-IPO Equity •••••• - 27 Jul 2023
Post-IPO Equity •••••• - 22 Jun 2022

View All 15 Funding Rounds

Tonix Pharmaceuticals Alternatives & Competitors

Tonix Pharmaceuticals vs

Biotech company independent development of innovative drugs + diagnostics for heart disease, cardiol...

Unknown
5 employees
Biotechnology

FAQ About Tonix Pharmaceuticals

Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) disorders, infectious diseases, immunology conditions, and rare diseases where there exists high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8mg), th...
Tonix Pharmaceuticals was founded in 2007.
Tonix Pharmaceuticals is headquartered in United States.
Tonix Pharmaceuticals operates in the following industries: Biopharma, Biotechnology, Pharmaceutical.
Tonix Pharmaceuticals has approximately 169 employees.
Tonix Pharmaceuticals has completed 15 funding rounds. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Tonix Pharmaceuticals include advanceCor GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Tonix Pharmaceuticals and advanceCor GmbH are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Tonix Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy